Does the media prefer CGON or RXRX?

In the previous week, CG Oncology and CG Oncology both had 7 articles in the media. CG Oncology's average media sentiment score of 1.05 beat Recursion Pharmaceuticals' score of 0.99 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COGT or RXRX?

In the previous week, Cogent Biosciences had 16 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 23 mentions for Cogent Biosciences and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Cogent Biosciences' score of 0.95 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or SRRK?

In the previous week, Scholar Rock had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 14 mentions for Scholar Rock and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Scholar Rock's score of 0.73 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RXRX or MIRM?

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 7 mentions for Recursion Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.41 beat Recursion Pharmaceuticals' score of 0.99 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ERAS or RXRX?

In the previous week, Erasca had 6 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 13 mentions for Erasca and 7 mentions for Recursion Pharmaceuticals. Erasca's average media sentiment score of 1.20 beat Recursion Pharmaceuticals' score of 0.99 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Recursion Pharmaceuticals (RXRX) Competitors

$3.51 -0.05 (-1.40%)

As of 03:16 PM Eastern

Compare

RXRX vs. CGON, COGT, SRRK, MIRM, and ERAS

Should you buy Recursion Pharmaceuticals stock or one of its competitors? Recursion Pharmaceuticals's main competitors and comparable companies include CG Oncology (CGON), Cogent Biosciences (COGT), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), and Erasca (ERAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Recursion Pharmaceuticals compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Recursion Pharmaceuticals has a net margin of -945.94% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

CG Oncology has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CG Oncology has higher earnings, but lower revenue than Recursion Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,720.80	-$160.99M	-$2.69	N/A
Recursion Pharmaceuticals	$74.68M	25.16	-$644.76M	-$1.04	N/A

In the previous week, CG Oncology and CG Oncology both had 7 articles in the media. CG Oncology's average media sentiment score of 1.05 beat Recursion Pharmaceuticals' score of 0.99 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology presently has a consensus price target of $83.18, suggesting a potential upside of 6.06%. Recursion Pharmaceuticals has a consensus price target of $8.06, suggesting a potential upside of 129.63%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Recursion Pharmaceuticals beats CG Oncology on 8 of the 15 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Cogent Biosciences presently has a consensus price target of $49.40, suggesting a potential upside of 34.39%. Recursion Pharmaceuticals has a consensus price target of $8.06, suggesting a potential upside of 129.63%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cogent Biosciences has higher earnings, but lower revenue than Recursion Pharmaceuticals. Cogent Biosciences is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Recursion Pharmaceuticals	$74.68M	25.16	-$644.76M	-$1.04	N/A

Cogent Biosciences has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

In the previous week, Cogent Biosciences had 16 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 23 mentions for Cogent Biosciences and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Cogent Biosciences' score of 0.95 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Summary

Recursion Pharmaceuticals beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Scholar Rock?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

In the previous week, Scholar Rock had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 14 mentions for Scholar Rock and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Scholar Rock's score of 0.73 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Recursion Pharmaceuticals has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Scholar Rock has lower revenue, but higher earnings than Recursion Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	25.16	-$644.76M	-$1.04	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Recursion Pharmaceuticals presently has a consensus target price of $8.06, suggesting a potential upside of 129.63%. Scholar Rock has a consensus target price of $58.77, suggesting a potential downside of 3.01%. Given Recursion Pharmaceuticals' higher probable upside, research analysts clearly believe Recursion Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Scholar Rock has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Scholar Rock	N/A	-160.19%	-87.18%

Summary

Recursion Pharmaceuticals and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 7 mentions for Recursion Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.41 beat Recursion Pharmaceuticals' score of 0.99 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Recursion Pharmaceuticals currently has a consensus price target of $8.06, suggesting a potential upside of 129.63%. Mirum Pharmaceuticals has a consensus price target of $137.33, suggesting a potential upside of 39.40%. Given Recursion Pharmaceuticals' higher possible upside, research analysts clearly believe Recursion Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	25.16	-$644.76M	-$1.04	N/A
Mirum Pharmaceuticals	$521.31M	12.27	-$23.36M	-$14.55	N/A

Mirum Pharmaceuticals has a net margin of -139.18% compared to Recursion Pharmaceuticals' net margin of -945.94%. Mirum Pharmaceuticals' return on equity of -36.28% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Recursion Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Erasca?

Erasca (NASDAQ:ERAS) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Erasca has higher earnings, but lower revenue than Recursion Pharmaceuticals. Erasca is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Recursion Pharmaceuticals	$74.68M	25.16	-$644.76M	-$1.04	N/A

Erasca has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Erasca's return on equity of -38.43% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Erasca has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

In the previous week, Erasca had 6 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 13 mentions for Erasca and 7 mentions for Recursion Pharmaceuticals. Erasca's average media sentiment score of 1.20 beat Recursion Pharmaceuticals' score of 0.99 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Erasca presently has a consensus price target of $22.09, suggesting a potential upside of 15.54%. Recursion Pharmaceuticals has a consensus price target of $8.06, suggesting a potential upside of 129.63%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Erasca beats Recursion Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.88B	$4.03B	$7.30B	$12.76B
Dividend Yield	N/A	3.63%	2.53%	10.79%
P/E Ratio	-3.38	11.62	272.85	24.16
Price / Sales	25.16	1,369.34	627.65	98.32
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	2.05	16.88	13.16	6.24
Net Income	-$644.76M	-$22.76M	$3.47B	$348.07M
7 Day Performance	0.29%	1.58%	1.31%	0.63%
1 Month Performance	18.58%	11.84%	8.67%	4.84%
1 Year Performance	-27.33%	57.30%	26.14%	16.90%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	2.1325 of 5 stars	$3.51 -1.4%	$8.06 +129.6%	-26.3%	$1.88B	$74.68M	N/A	400	Options Volume
CGON CG Oncology	2.8326 of 5 stars	$75.03 +0.4%	$83.18 +10.9%	+210.6%	$6.62B	$4.04M	N/A	61	Positive News
COGT Cogent Biosciences	2.8209 of 5 stars	$37.93 +1.7%	$49.10 +29.4%	+212.1%	$6.47B	N/A	N/A	80	News Coverage
SRRK Scholar Rock	1.5524 of 5 stars	$52.52 -1.0%	$57.71 +9.9%	+74.8%	$6.46B	N/A	N/A	140
MIRM Mirum Pharmaceuticals	3.6308 of 5 stars	$100.64 +1.9%	$137.33 +36.5%	+36.6%	$6.41B	$521.31M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. CGON, COGT, SRRK, MIRM, and ERAS

How does Recursion Pharmaceuticals compare to CG Oncology?

Summary

How does Recursion Pharmaceuticals compare to Cogent Biosciences?

Summary

How does Recursion Pharmaceuticals compare to Scholar Rock?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. CGON, COGT, SRRK, MIRM, and ERAS

How does Recursion Pharmaceuticals compare to CG Oncology?

Is CGON or RXRX more profitable?

Which has more volatility & risk, CGON or RXRX?

Do institutionals & insiders hold more shares of CGON or RXRX?

Which has better valuation & earnings, CGON or RXRX?

Does the media prefer CGON or RXRX?

Do analysts recommend CGON or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Cogent Biosciences?

Do analysts recommend COGT or RXRX?

Do institutionals & insiders hold more shares of COGT or RXRX?

Which has stronger valuation and earnings, COGT or RXRX?

Is COGT or RXRX more profitable?

Does the media refer more to COGT or RXRX?

Which has more risk and volatility, COGT or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Scholar Rock?

Does the media refer more to RXRX or SRRK?

Which has more risk and volatility, RXRX or SRRK?

Which has better earnings & valuation, RXRX or SRRK?

Do insiders & institutionals hold more shares of RXRX or SRRK?

Do analysts recommend RXRX or SRRK?

Is RXRX or SRRK more profitable?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Does the media favor RXRX or MIRM?

Do analysts rate RXRX or MIRM?

Do institutionals and insiders hold more shares of RXRX or MIRM?

Which has higher earnings and valuation, RXRX or MIRM?

Is RXRX or MIRM more profitable?

Which has more risk and volatility, RXRX or MIRM?

Summary

How does Recursion Pharmaceuticals compare to Erasca?

Which has stronger earnings & valuation, ERAS or RXRX?

Is ERAS or RXRX more profitable?

Which has more volatility & risk, ERAS or RXRX?

Does the media refer more to ERAS or RXRX?

Do insiders & institutionals have more ownership in ERAS or RXRX?

Do analysts prefer ERAS or RXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools